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Abstract
Background:  L-threonine is an indispensable amino acid. One of the major L-threonine
degradation pathways is the conversion of L-threonine via 2-amino-3-ketobutyrate to glycine. L-
threonine dehydrogenase (EC 1.1.1.103) is the first enzyme in the pathway and catalyses the
reaction: L-threonine + NAD+ = 2-amino-3-ketobutyrate + NADH. The murine and porcine L-
threonine dehydrogenase genes (TDH) have been identified previously, but the human gene has
not been identified.
Results: The human TDH gene is located at 8p23-22 and has 8 exons spanning 10 kb that would
have been expected to encode a 369 residue ORF. However, 2 cDNA TDH transcripts encode
truncated proteins of 157 and 230 residues. These truncated proteins are the result of 3 mutations
within the gene. There is a SNP, A to G, present in the genomic DNA sequence of some individuals
which results in the loss of the acceptor splice site preceding exon 4. The acceptor splice site
preceding exon 6 was lost in all 23 individuals genotyped and there is an in-frame stop codon in
exon 6 (CGA to TGA) resulting in arginine-214 being replaced by a stop codon. These truncated
proteins would be non-functional since they have lost part of the NAD+ binding motif and the
COOH terminal domain that is thought to be involved in binding L-threonine. TDH mRNA was
present in all tissues examined.
Conclusions: The human L-threonine 3-dehydrogenase gene is an expressed pseudogene having
lost the splice acceptor site preceding exon 6 and codon arginine-214 (CGA) is mutated to a stop
codon (TGA).
Background
Liver failure is a cause of considerable mortality; therefore
bioartificial livers may offer significant therapeutic bene-
fit. Porcine-derived hepatocytes are being used in clinical
studies of bioartificial livers [1,2]. There may, however, be
significant differences in the activities of liver enzymes be-
tween species [3]. These differences are also important
considerations when the pharmaceutical industry con-
ducts new drug metabolism and pharmacokinetic studies
on key mammal species [4].
The liver plays a critical role in regulating the circulating
concentrations of amino acids. The regulation of amino
acid supply to bioartificial organs and maintaining the ac-
tivity of the amino acid-metabolising enzymes will be im-
portant in their development. Active maintenance of the
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optimal amino acid concentrations will offer the possibil-
ity of prolonging the differentiated function of hepato-
cytes in bioartificial livers [5].
L-threonine is one of three indispensable amino acids
since mammals do not possess the necessary enzymes for
the transamination of threonine [6]. However, the tran-
sient apoenzyme form of L-threonine dehydratase bound
to pyridoxamine 5'-phosphate dehydratase can carry out a
half-transamination of L-threonine [7]. Once L-threonine
is oxidised through various catabolic pathways it is lost for
the purposes of protein synthesis. Therefore, it is impor-
tant for determining levels of human nutrition that factors
regulating threonine oxidation are identified. The interna-
tional recommended intake of L-threonine for adults is 7
mg.kg-1.d-1[8]. However, this has recently been chal-
lenged as being too low and a recommendation of 15
mg.kg-1.d-1 has been suggested [9].
There are two major L-threonine degradation pathways. L-
threonine is either catabolised by L-threonine 3-dehydro-
genase to 2-amino-3-ketobutyrate or by L-serine/threo-
nine dehydratase (EC 4.2.1.16) to NH4
+ and 2-
ketobutyrate. In both eukaryotic and prokaryotic cells, the
conversion of L-threonine via 2-amino-3-ketobutyrate to
glycine takes place in a two-step process [10,11]. L-threo-
nine dehydrogenase catalyses the reaction: L-threonine +
NAD+ = 2-amino-3-ketobutyrate + NADH. The subse-
quent reaction between 2-amino-3-ketobutyrate and
coenzyme A to form glycine and acetyl-CoA is catalysed by
2-amino-3-ketobutyrate coenzyme A ligase (EC 2.3.1.29
also called glycine acetyltransferase; gene names KBL and
GCAT). L-threonine dehydrogenase and 2-amino-3-keto-
butyrate coenzyme A ligase are associated physically on
the inner membrane-matrix of mitochondria where the
two enzymes form a complex with a stoichiometry of one
threonine dehydrogenase tetramer to two 2-amino-3-ke-
tobutyrate coenzyme A ligase dimers [12–14].
In mammals, the removal of the 1-carbon of threonine is
thought to occur through threonine dehydrogenase, this
carbon being incorporated into glycine and released as
CO2 by the mitochondrial glycine cleavage system. In nor-
mally-fed pigs and rats 80 to 87% of L-threonine catabo-
lism occurs via threonine dehydrogenase [15,16] and in
isolated rat and cat hepatocytes 35% to 50% of threonine
oxidation occurs through this pathway [17,18]. Zhao et al.
measured threonine oxidation in adult humans by the
production of labelled CO2 from L-[1-13C]threonine and
concluded that the conversion of threonine to glycine
through the threonine dehydrogenase pathway was not
important if it exists at all [19]. However, the dehydroge-
nase pathway is thought to account for 44% of total thre-
onine oxidation in infants [20]. More recently, the same
group used a more sensitive method to measure the pro-
duction of labelled glycine and CO2 in adults and suggest-
ed that there was some threonine catabolism via the
threonine dehydrogenase pathway, but it accounted for
only 7–11% of total [21]. This suggested that the L-serine/
threonine dehydratase pathway is the dominant route in
the catabolism of threonine in humans.
Recently, the sequences of the murine and porcine TDH
cDNAs have been reported [22]. The amino-terminal re-
gions of these proteins have characteristics of a mitochon-
drial targeting sequence and are related to the UDP-
galactose 4-epimerases, with both enzyme families having
an amino-terminal NAD+ binding domain. The sequence
of the human KBL transcript, the second enzyme in the
pathway, has also been described [23] and this study
aimed to identify the human TDH gene.
Results
Human TDH gene
The murine L-threonine 3-dehydrogenase gene (TDH) has
recently been identified [22]. The human genome was
searched using this murine sequence and only a single pu-
tative human TDH gene was found to be present. The pu-
tative human TDH gene is located on clone RP11-110L10,
chromosome 8p23-22 (GenBank accession No.
AC011959, Whitehead Institute/MIT Center for Genome
Research, USA), between the gene for acyl-malonyl con-
densing enzyme and hypothetical protein, C8orf13 gene
(accession No. XP_088377) (Figure 1A). By comparison
with the murine TDH gene and the porcine cDNA, 8 hu-
man exons were identified spanning 10 kb (Figure 1B).
The predicted start of the ORF is in good sequence context
for the initiation of translation [24].
The sequence of the human TDH exons (Fig. 2) has 84%
identity with the porcine cDNA at the nucleotide level in
the ORF and the theoretical full-length human protein has
85% identity and 97% similarity with the porcine TDH
protein [22], suggesting that this is the human TDH gene.
The first potential polyadenylation signal site (ATTAAA) is
also conserved between species.
Human TDH protein
The predicted human TDH protein possesses very weak
similarity to the human uridine diphosphogalactose-4-
epimerase protein (GALE). GALE catalyses the intercon-
version of UDP-galactose and UDP-glucose in the meta-
bolic pathway that converts galactose into glucose1-
phosphate, and also catalyses the interconversion of UDP-
GalNAc and UDP-GlcNAc. An alignment of the human
TDH protein with other eukaryotic TDH protein sequenc-
es and GALE proteins from Homo sapiens and Escherichia
coli identified conserved residues likely to contact the
nicotinamide-adenine-dinucleotide cofactor (NAD+)
(Fig. 3) [25]. They are Gly-58, Gly-61, Gly-64, Asp-84,BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/18
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Asp-102, Ile-103, Leu-104, His-123, Leu-127, Val-142,
Asn-143, Ser-165, Tyr-191, Lys-195 and Tyr-218 [26–29].
In view of the different substrates utilised by the 2 en-
zymes, of those 22 residues that contact the sugar sub-
strate in GALE only one, Asp-325, is conserved (excluding
those residues involved in contact with both sugar and
NAD+).
Human TDH predicted secondary structure
Using the translation of the human genomic sequence
(with the stop codon replaced with the conserved arginine
residue found in other TDH proteins) the predicted sec-
ondary structure of the likely "ancestral" TDH protein was
determined using Psi-Pred [30] and aligned with the crys-
tal structure of GALE from E. coli[29,31] (Fig. 4). The hu-
man ancestral TDH protein would have been a mixed
alpha-helices/beta-sheet protein with a NAD+ binding
Rossmann-fold and belongs to the tyrosine-dependent
oxidoreductase protein family (also known as short-chain
dehydrogenases). The characteristic Tyr-x-x-x-Lys couple
(residues 191 and 195) found in all family members is
important for catalysis with the conserved tyrosine serving
as the active-site base [33]. Two domains were identified,
with the larger amino-terminus domain (residues 53–
234) having a NAD+ binding motif and the smaller car-
boxy-terminus domain (residues 218–329) likely to be in-
volved in L-threonine binding. It is likely that the
substrate is located in the cleft between the two domains.
Mutations in the human TDH gene
However, there are 3 mutations that disrupt the gene tran-
scription and translation on the sequence of genomic
clone RP11-110L10 (Fig. 2). There is a loss of the acceptor
splice sites in exon 4 and 6 and an in-frame stop codon in
exon 6 (from the expected CGA to TGA) resulting in ar-
ginine-214 being replaced by a stop codon. Together,
these mutations suggested that the human TDH gene is a
pseudogene.
To determine whether these mutations were present in
other species, sequence alignments around the acceptor
splice sites in exons 4 and 6 were constructed (Fig. 5). The
genomic sequences from the mouse and puffer fish (Tak-
ifugu rubripes or Fugu) and another human genomic clone
(AF131216, Institute of Molecular Biotechnology, Germa-
ny) have intact acceptor splice sites in exon 4 suggesting
that the loss of this splice site is a single nucleotide poly-
morphism (SNP) (Fig. 5A). In both human genomic DNA
Figure 1
Chromosomal localisation and gene structure of the human TDH gene. (A) The human TDH gene is located at 8p23 and the
neighbouring genes are: myotubularin related protein 8, MTMR8: acyl-malonyl condensing enzyme, AMAC: threonine dehydro-
genase, TDH: hypothetical protein, C8orf13; B lymphoid tyrosine kinase, BLK. Genes encoded by + and - stands are shown
above and below the line respectively. The telomeric and centromeric directions are indicated. (B) The human TDH gene
spans 10 kb and consists of 8 exons. The putative initiation methionine codon, stop codon and poly-adenylation signal are








Exon 1 2 3 4 5 6 7 8
1kb
AAGAAAATGC TGA ATTAAA
172 43 71 150 173 91 270 137/369
Intron 1844 1235 2102 99 1075 1744 593BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/18
Page 4 of 13
(page number not for citation purposes)
sequences the acceptor splice site in exon 6 is lost, but it is
intact in both the mouse and puffer fish sequences (Fig.
5B). Similarly, the stop codon is present in both human
genomic DNA sequences, but it is not present in genomic
DNA, cDNA and EST sequences from other species. In hu-
man genomic DNA sequence (AC011959) there is also an
A to T mutation in codon 201 (ATG to TTG, in exon 5) re-
sulting a methionine to leucine substitution.
Genotyping of individuals by restriction enzyme digests 
and DNA sequencing
To determine whether these mutations in the 2 human ge-
nomic sequences were sequencing errors or just present in
those individuals utilised for determining the human ge-
nome, the region encompassing the mutations was ampli-
fied by PCR from a number of individuals, sequenced and
digested with restriction enzymes. Amplicons from the
exon 4 splice acceptor site were digested with the restric-
tion enzyme AciI. If the acceptor splice site was not present
(G^CGG rather than GCAG, acceptor splice site under-
Figure 2
Sequence and translation of the human TDH exons. A comparison of the human genomic sequence with the murine TDH gene
enabled the identification of 8 homologous exons on clone RP11-110L10. A translation of the exons is shown below the nucle-
otide sequence. The acceptor and donor splice sites (AG &GT) at the ends of each exon are shown in uppercase and under-
lined. The potential polyadenylation signal and site (attaaa and c) are shown in bold and underlined.
Exon 1
gtatttgaaaagaaaatgctgttcattaggatgctgaggcgagcggggcagagcccagcctgtggctgttggacgcctgtcctgccggtccgctttctgggcatc
               M  L  F  I  R  M  L  R  R  A  G  Q  S  P  A  C  G  C  W  T  P  V  L  P  V  R  F  L  G  I 
tcccctcggcaaattccagcagatgctaacttccactctgcgtctttctctgacacagaccatccacgagtcttaattacagGT
S  P  R  Q  I  P  A  D  A  N  F  H  S  A  S  F  S  D  T  D  H  P  R  V  L  I  T  G
Exon 2
AGgggctcttggccagctgggagtggggcttgctaatcttttgagGT
    A  L  G  Q  L  G  V  G  L  A  N  L  L  R
Exon 3
AGgaaacgatttggaaaggacagtgtgattttgtctgacataaggaaaccccccgatcatgtctttcacagtgGT
   K  R  F  G  K  D  S  V  I  L  S  D  I  R  K  P  P  D  H  V  F  H  S  G
Exon 4
GGgtccattcatttattctgatatcttggattacaagaatcttcgggagatcgtggtaaacaaccgcatcacctggctgtttcattacag
    P  F  I  Y  S  D  I  L  D  Y  K  N  L  R  E  I  V  V  N  N  R  I  T  W  L  F  H  Y  S
cgctttgctcagcgcctttggagaagcaaatgtttccctggcgagagcagtgaatataactgGT
 A  L  L  S  A  F  G  E  A  N  V  S  L  A  R  A  V  N  I  T  G
Exon 5
AGgcctgcataacatcctggatgtcgctgcggaacacaatctgcaattgtttgtgcctagcacgattggggcttttggacccacctctcc
    L  H  N  I  L  D  V  A  A  E  H  N  L  Q  L  F  V  P  S  T  I  G  A  F  G  P  T  S  P
ccggaacccaacccccgatctctgtattcagagacccaggaccatctatggggtgtccaaggtccacgcggagctcttgggagaaGT
 R  N  P  T  P  D  L  C  I  Q  R  P  R  T  I  Y  G  V  S  K  V  H  A  E  L  L  G  E
Exon 6
GGtattatcattaccggtatgggttagatttctgatgcctgagatatcctggaatcatttcagctgactcccagcctggaggaggaacaactgGT
  Y  Y  H  Y  R  Y  G  L  D  F  *  C  L  R  Y  P  G  I  I  S  A  D  S  Q  P  G  G  G  T  T  D
Exon 7
AGactatgcagtccagattttccatgatgccacaaagcatggcaaattcgagtgcaacctggaagcctgcacgagactgcccatgatgta
    Y  A  V  Q  I  F  H  D  A  T  K  H  G  K  F  E  C  N  L  E  A  C  T  R  L  P  M  M  Y 
cattgacgactgcctcagagccaccctggaggtcatggaggccccagctgagtccctttccatgaggacctacaatgtcagcgccatgag
 I  D  D  C  L  R  A  T  L  E  V  M  E  A  P  A  E  S  L  S  M  R  T  Y  N  V  S  A  M  S 
cttcacacccgaggagctggcccaggaggtcctcaagcacgtgccggaattccagatcacatacaacgtggatgccgttcgccaggccatagGT
 F  T  P  E  E  L  A  Q  E  V  L  K  H  V  P  E  F  Q  I  T  Y  N  V  D  A  V  R  Q  A  I  A  
Exon 8
AGcggatggttggccgatgaactttgatgacagcaatgctcggaaggactgggggtggaaacacgactttgatcttccagagttggtgac
    D  G  W  P  M  N  F  D  D  S  N  A  R  K  D  W  G  W  K  H  D  F  D  L  P  E  L  V  T 
tgccatgttgaacttccatggttctgaaagcagagttgcccaagccaactgaaagaatctggaagaggagctcctgtgtcctggtccact
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lined) the 158 bp amplicon was digested to produce re-
striction fragments of 104 and 54 bp. The restriction
enzyme digest pattern and DNA sequence of 3 individuals
are illustrated (Fig. 6) in which one individual has the
splice site intact, another has lost the splice site and the
third has the heterozygous condition. Digestion is not as
complete as would be expected in the heterozygous con-
dition, presumably due to heteroduplex formation during
the PCR. This SNP was found in 20 out of 40 chromo-
somes examined.
Amplicons from the exon 6 splice acceptor site from 3 in-
dividuals were digested with the restriction enzyme
Hsp92II. If the acceptor splice site was not present
(CATG^g rather than CATAg) the 207 bp amplicon was
digested to produce restriction fragments of 112 and 95
bp. Three individuals examined had lost the splice site
Figure 3
Clustal alignment of the predicted human protein with other eukaryotic L-threonine dehydrogenase (TDH) protein sequences
and 2 UDP-galactose 4-epimerase sequences (GALE). The species and the derivation of the sequences are as follows: Homo
sapiens, HsTDH, genomic DNA (accession No. AC011959); HsGALE, cDNA (NP_000394); Sus scrofa, (pig), Ss, cDNA
(AY095535); Mus musculus, mouse, Mm, cDNA (AY116662); Danio rerio (zebrafish), Dr, ESTs (electronic contigous sequence);
Takifugu rubripes (puffer fish), Tr, genomic DNA, (AF411956); Ciona intestinalis (a tunicate), Ci, ESTs; Drosophila melanogaster,
Dm, genomic DNA gene CG5955 and ESTs; Caenorhabditis elegans, Ce, genomic DNA (U64847) and ESTs; Escherichia coli,
EcTDH (P07913) and EcGALE (AAC73846). The locations of the exon/exon boundaries are shown on the translated protein
as underlined residues. Conserved residues are indicated by a (*), strongly similar residues by a (:) and weakly similar residues
by a (.). Residues that are common to at least two protein sequences are shown in bold. The in-frame stop codon in the human
sequence is indicated by a red (#). Gale protein residues in contact with the ligand nicotinamide-adenine-dinucleotide are high-
lighted in green and those residues in contact with the sugar ligands, uridine-5'-diphosphate-mannose and uridine-5'-diphos-
phate-4-deoxy-4-fluoro-alpha-d-galactose are highlighted in yellow. Those residues that have been shown to contact both
NAD and sugar are highlighted in light blue [26–29].
HsTDH    MLFIRMLRRAG----QSPACGCWTPVLPVRFLGISPRQIP--ADANFHSASFSDTDHPRVLITGALGQLGVGLANLLRKRFGKDSVILSDIRKPPDH---------------VFHSGP  97
SsTDH    MPVVKMLKQVASRTLGSPACGCQPPTLPRRFLGTSPRQIP--ADANFHSTSFSEANQPRVLITGGLGQLGVGLASLLRKRFGKDNVILSDIRKPPEH---------------VFLSGP 101
MmTDH    MLFLGMLKQVVNGTAQSKASSCRKLVLPLKFLGTSQHRIP--ADANFHSTSISEAEPPRVLITGGLGQLGVGLANLLRKRFGKDNVILSDIRKPPAH---------------VFHSGP 101
DrTDH    MPVIRALSKVAKQALLAPACGCQPLTVAIRNISFSPRQVTSASDASFHSVSFSETDHPKVLITGGLGQLGVGLAKLLRKRFGKNNVILSDIRKPPSN---------------VFHSGP 103
TrTDH         MRPPACVRAAAALGLSCRGCLRFGGFSSWRRQMSR--WNDQENCCPQPPQEAPRILITGGLGQLGVGLAQMLRKQYGTDNVILSDIKKPSPD---------------VYKSGP  96
CiTDH       MKNITEICR---VTLKQLGKSACHG---SNKSTVFAS--SRRNYSDSE-ASNKEKRIIITGGLGQLGQGLAKKLRSKYGRENVLLTDIRIPDKS---------------IVKEGP  91
DmTDH         MFRKCLAS--LALAPVASPIPLP-RITPIASQLVQ---RRAFHQVP-RESRPPKILITGGLGQLGIECAKLLRTQYGSQNVILSDIIKPSQS---------------VLENGP  91
CeTDH       MKNLRVFG----RIHNARRNYSPLP------VDPLLR------FKTIS-QTQKAPRVLITGSLGQLGRGLNSVYKYMYGSECVVMSDIVRLPAN---------------ATDVSD  83
EcGALE                                                            MRVLVTGGSGYIGS-HTCVQLLQNGHD-VIILDNLCNSKRS------VLPVIERLGGKHPT  53
HsGALE                                                          MAEKVLVTGGAGYIGS-HTVLELLEAGYL-PVVIDNFHNAFRGGGSLPESLRRVQELTGRSVE  61
::::**. * :*           *    :: *                         
HsTDH  FIYSDILDYKNLREIVVNNRITWLFHYSALLSAFGEANVSLAR-AVNITGLHNILDVAAEHNLQ-LFVPSTIGAFGPTSPRNPTPDLCIQRPRTIYGVSKVHAELMG-EYYHYRYGLDF# 214
SsTDH  FIYSDILDYKNLREIVVNNRVTWLFHYSALLSAVGEANVSLAR-AVNITGLHNVLDVAAEHGLR-LFVPSTIGAFGPTSPRNPTPDLCIQRPRTIYGVSKVHAELMG-EYYYYRYGLDFR 218
MmTDH  FVYANILDYKSLREIVVNHRISWLFHYSALLSAVGEANVSLAR-DVNITGLHNVLDVAAEYNVR-LFVPSTIGAFGPTSPRNPAPDLCIQRPRTIYGVSKVHTELMG-EYYYYRYGLDFR 218
DrTDH  FIYSDILDYKNLREIVVNNRITWLVHYSALLSAVGEANVALAR-AVNITGLHNILDIAAEHGLR-LFVPSTIGAFGPTSPRNPTPDLCVQRPRTIYGVSKVHAELMG-EYYHHRYGLDFR 220
TrTDH  FVYADVLDYKLLRELIVNNRITWLVHYSALLSAVGEANVALAR-KINITGLHNVLDLALENCLR-LFVPSTIGAFGPSSPRDPAPDLCVQRPRTIYGVSKVHGELMG-EYLHHKYGLDFR 213
CiTDH  YAYADTLNYDAIKELAVNHRADWLIHFSALLSAVGEANVPLAV-KVNINGMHNVLDVANELGLK-LFIPSTIGAFGTDSPRNPTPDVCIQRPKTIYGVAKVHAERMG-EYYHHRFNLDFR 208
DmTDH  YIFADILDFKGLQKIVVDHRIDWLIHFSALLSAVGEQNVPLAV-RVNIEGVHNVIELAKQYKLR-IFVPSTIGAFGPDSPRNPTPNVTIQRPRTIYGVSKVHAELIG-EYYYHKFGLDFR 208
CeTDH  YNYLDILNQGSIEEIVVNKNIDTIVHFSALLSAVGETNVPLAL-QVNCRGVENILQVAAKHKLK-VFIPSTIGAFGPTTPRENTPDLTVQCPTTIYGVSKVYAERLG-EYFNHRFGVDFR 200
EcGALE FVEGDIRNEALMTEILHDHAIDTVIHFAGLKAVGESVQKPLEYYDNNVNGTLRLISAMRAANVKNFIFSSSATVYGDQPKIPYVESFPTGTPQSPYGKSKLMVEQILTDLQKAQPDWSIA 173
HsGALE FEEMDILDQGALQRLFKKYSFMAVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMKAHGVKNLVFSSSATVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNVV 181
:   :  :   : .:  .     :.*::.* :.  . : .*     *  *  .::.      :: ....*:  .:*                 . ** :*.  * :  :        .. 
HsTDH  CLRYPGIISADSQ------PGGGTTDYAVQIFHDATKH-------GKFECNLEACTRLPMMYIDDCLRATLEVMEAPAESLSMRTYNVSAMSFTPEELAQEVLKHVPEFQITYNVDAVRQ 321
SsTDH  CLRYPGIISADSQ------PGGGTTDYAVQIFQDAVKN-------GRFECNLNPGTKLPMMYIDDCLRATLEVMEAPAEALSLRTYNVNAMSFTPAELAQEVLKHIPEFQITYNVDSVRQ 325
MmTDH  CLRYPGIISADSQ------PGGGTTDYAVQIFHAAAKN-------GTFECNLEAGTRLPMMYISDCLRATLEVMEAPAERLSMRTYNISAMSFTPEELAQALRKHAPDFQITYCVDPLRQ 325
DrTDH  CLRYPGIISADSQ------PGGGTTDYAVQIFHDAVKT-------GKFECNLKPDTRLPMMYIDDCLRATLEVMEAPLETLSMRTYNINAMSFTPEELANEVQKQLPDLQVSYEIDSVRQ 327
TrTDH  CLRYPGVISVNTT------PGGGTTDYAVQIFHDALST-------GHHECYLRPETRLPMMHIADCHRATVEFMQAPECQLTLRTYNIAAMSFTPEEVAQEIRKHLPHLKVTYNPDVVRQ 320
CiTDH  CLRFPGIISCDTK------PGGGTTDYAVEIFHKALSN-------GSFVCNVAPDTRLPMMQIDDCLDATIKFMETDVSKLHQRVYNINSMSFTPEELAHEIRKHIPNFEITYDVNPMLQ 315
DmTDH  CLRFPGVISSDP-------PGGGTTDYAVAVFHEALRN-------GKYTCYLRPDTRLPMMYIEDCLRALLEFMRAPNEQLKRRVYNVTAMSFTPEELFAQLGKHVPNLHVTYKPDS-RQ 313
CeTDH  SMRFPGIISATK-------PGGGTTDYAIQIFYDALQK-------GKHTCYLRPDTRLPMMYDTDCMASVIQLLAADSQSLKRRTYNVTGFSFTPEEIADAIRRVMPGFEIDYDICPTRQ 306
EcGALE LLRYFNPVGAHPSGDMGEDPQGIPNNLMPYIAQVAVGRRDSLAIFGNDYPTEDGTGVRDYIHVMDLADGHVVAMEKLANKPGVHIYNLGAGVGNSVLDVVNAFSKACGKPVNYHFAP--R 291
HsGALE LLRYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRDYIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYSVLQMVQAMEKASGKKIPYKVVA--R 299
:*: .  .          * * ..:    :   *          *         :   *   . :  :         : **:      .               : *      :
HsTDH  AIADGWPMNFDDSNARKDWGWKHDFDLPELVTAMLNFHGSESRVAQAN             369
SsTDH  AIADSWPMNFDDSTARRDWGWKHDFDLPELVTTMLNFHGAHSRVAQAN             373
MmTDH  AIAESWPMILDDSNARKDWGWKHDFDLPELVATMLNFHGVSTRVAQVN             373
DrTDH  AIADSWPMNFDDTNARNDWGWKHDYDLPELVQTMLNYIGSESRIAQAN             375
TrTDH  SIADSWPVRFDDSNARRDWGWTPVFGLEELVTDMLNSIQSRRAKEGLPAS           370
CiTDH  EIADSWPDVFEDDNSRRDWEWEHKYDLSKLVKYMLEGIKKQMW                  358
DmTDH  LIADAWPQVFDDSDARRDWHWQHKYDLSNLVDFMIKDVQDNYINVQPEQQTLQI       367
CeTDH  SIADSWPMSLDDSEARKDWGWNPEYGLDETVQVMFALLRREEDKPTKIVSTA         358
EcGALE REGDLPAYWADASKADRELNWRVTRTLDEMAQDTWHWQSRHPQGYPD              338
HsGALE REGDVAACYANPSLAQEELGWTAALGLDRMCEDLWRWQKQNPSGFGTQA            348
 .:  .   :   : .:  *     * .BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/18
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Figure 4
Predicted secondary structure of human "ancestral" TDH protein was determined using the Psi-Pred program and was aligned
with that of the crystal structure of uridine diphosphogalactose-4-epimerase protein (GALE) from Escherichia coli[29,31] using
3D-PSSM. The labels are: human "ancestral" TDH protein predicted secondary structure, HsTDH_PSSM; human "ancestral"
TDH protein sequence, HsTDH_seq; E. coli GALE protein sequence, EcGale_seq; E. coli GALE protein secondary structure,
1udc_SS; alpha-helix, H, highlighted in light blue; beta-sheet, E, highlighted in yellow; c = turn, coil or loop. Identical residues are
shown and additionally, a ":" indicates positive equivalence.
HsTDH_PSSM   CCCHHHHCCCCCCCCCCCCCCEEEEEECCCCCCCCCCCCCCCCCCCCCCC
HsTDH_seq    MLFIRMLRRAGQSPACGCWTPVLPVRFLGISPRQIPADANFHSASFSDTD  50
HsTDH_PSSM   CCEEEEECCCCHHHHHHHHHHHHCCCCEEEEECCCCCCCHHHCC------
HsTDH_seq    HPRVLITGALGQLGVGLANLLRKRFGKDSVILSDIRKPPDHVFH------  94
 :RVL:TG: G::G:::: :L: : G:D::IL:::::: : V::------
EcGale_seq    MRVLVTGGSGYIGSHTCVQLLQN-GHDVIILDNLCNSKRSVLPVIERLG  48
1udc_SS      CEEEEECCCCHHHHHHHHHHHHH-CCEEEEEECCCCCCCHHHHHHHHHH
HsTDH_PSSM --CCEEEEECCCCHHHHHHHHHHCCCCEEEECCCCCCCCCCC-CHHHHHH
HsTDH_seq --SGPFIYSDILDYKNLREIVVNNRITWLFHYSALLSAFGEA-NVSLARA  141
--  :F:::DI:: ::: EI: :: I: ::H:::L:::::::- ::::::
EcGale_seq   GKHPTFVEGDIRNEALMTEILHDHAIDTVIHFAGLKAVGESVQKPLEYYD  98
1udc_SS     CCCCEEEECCCCCHHHHHHHHHHHCCCEEEECCCCCCHHHHHHCHHHHHH
HsTDH_PSSM   CCCHHHHHHHHHHHHCCCCEEEEEECCCCCCCCCCCCCCCCCCCC-CCCH
HsTDH_seq    VNITGLHNILDVAAEHNLQLFVPSTIGAFGPTSPRNPTPDLCIQR-PRTI 190
 :N: G:: :: ::: :N:: F::S:::::::: P::P  :: :::-P ::
EcGale_seq   NNVNGTLRLISAMRAANVKNFIFSSSATVYGDQPKIPYVESFPTGTPQSP 148
1udc_SS    HHHHHHHHHHHHHHHHCCCEEEEEEEHHHHCCCCCCCCCCCCCCCCCCCH
HsTDH_PSSM HHHHHHHHHHHHHHHHHHC-CCCEEEEECCCCCCCCC------CCCCCCC
HsTDH_seq    YGVSKVHAELMGEYYHYRY-GLDFRCLRYPGIISADS------QPGGGTT 233
 YG SK:::E::: :  :: -:: :  LRY:::::A::------:P G:::
EcGale_seq   YGKSKLMVEQILTDLQKAQPDWSIALLRYFNPVGAHPSGDMGEDPQGIPN 198
1udc_SS    HHHHHHHHHHHHHHHHHHCCCCEEEEEEECEEECEECCCCEECCCCCCCC
HsTDH_PSSM   CHHHHHHHHHHCCCC-EEEEC------CCCCEEEEEEHHHHHHHHHHHHH
HsTDH_seq    DYAVQIFHDATKHGK-FECNL------EACTRLPMMYIDDCLRATLEVME 276
 :::::I:::A: :: -: :::------::: ::::::::D:::::: :ME
EcGale_seq   NLMPYIAQVAVGRRDSLAIFGNDYPTEDGTGVRDYIHVMDLADGHVVAME 248
1udc_SS     CHHHHHHHHHHCCCCCEEEECCCCCCCCCCCEECEEEHHHHHHHHHHHHH
HsTDH_PSSM   CCCCCCCEEEEEEC-CCCCCHHHHHHHHHHHHCCCCCCEEECCCCCCCCC
HsTDH_seq    APAESLSMRTYNVS-AMSFTPEELAQEVLKHVPEFQITYNVDAVRQAIAD 325
 ::A:: : ::YN::-: : ::::::::: K::::-:: Y ::::R :: :
EcGale_seq   KLANKPGVHIYNLGAGVGNSVLDVVNAFSKACGK-PVNYHFAPRREGDLP 297
1udc_SS    HHCCCCEEEEEEECCCCCEEHHHHHHHHHHHHCC-CCCEEEECCCCCCCC
HsTDH_PSSM   CEEECCCHHHHHHHCCCCCCCCHHHHHHHHHHHHHHCCCCCCCC
HsTDH_seq    GWPMNFDDSNARKDWGWKHDFDLPELVTAMLNFHGSESRVAQAN   369
  :::—-D S:A ::: W:  ::L:E:: ::::::: ::: 
EcGale_seq   AYWA—-DASKADRELNWRVTRTLDEMAQDTWHWQSRHPQGYPD    338
1udc_SS     CCCC--CHHHHHHHHCCCCCCCHHHHHHHHHHHHHHCCCCCCCBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/18
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(Fig. 7). DNA sequencing verified the loss of the splice site
and the presence of the in-frame stop codon in exon 6 in
all 20 individuals examined (data not shown).
Copy DNA sequences of the human TDH gene
The human TDH gene is expressed. PCR amplification
from cDNA libraries using primers designed to amplify
the TDH ORF was carried out and amplicons of approxi-
mately 1000 bp were obtained from cDNAs from 2 indi-
viduals, cloned and sequenced. The 1019 bp sequence of
clone 1 (AY101186) skipped exon 6, resulting in a prema-
ture stop codon in exon 7, (Fig. 8A) and would encode a
230 residue ORF (Fig. 8B). The 935 bp sequence of clone
2 (AY101187) skipped exon 4 and utilised a cryptic splice
site in exon 6, 24 bp downstream of the expected site (Fig
5B), resulting in a premature stop codon in exon 6 (Fig.
8A) and would encode a 157 residue ORF (Fig. 8B). The
human TDH gene is therefore a pseudogene since all indi-
viduals examined contain at least 2 mutations that on
translation would generate truncated proteins that would
be non-functional since they would be unable to make ap-
propriate contacts with the substrates, L-threonine and
NAD+.
Expression of the TDH pseudogene in human tissue and 
cell types
Reverse-transcriptase PCR was used to determine the pres-
ence of the TDH pseudogene mRNA in different tissues
and cell types. TDH expression was found in all tissues ex-
amined (Fig. 9A). TDH mRNA was present in most cell
types examined, but was below the level of detection in
Figure 5
Comparison of the human TDH gene sequences in the region of exon 4 and 6 acceptor sites with those of other species. (A)
The splice donor and acceptor sites are indicated (gt and ag respectively). There is a splice site mutation in exon 4 in one of the
human genomic sequences (gg, coloured red). The translations of the genes are shown below the DNA sequences (ORF). The
species and accession numbers are: Homo sapiens, HsTDH_gDNA_A (AF131216); HsTDH_gDNA_B (AC011959); Mus muscu-
lus, MmTDHgDNA (14.54000001-55000000 supercontig, Sanger Centre, UK) and puffer fish, Takifugu rubripes, TrTDH_gDNA
(AF411956). (B) There is an in-frame stop codon (TGA, coloured blue) and a splice site mutation in exon 6 in the human
genomic sequence (AF131216). A cryptic splice site (ag, coloured red) was utilised in cDNA clone 1 that altered the reading
frame, resulting in another stop codon (TGA, coloured green). The species and accession numbers are: pig, Sus scrofa,
SsTDH_cDNA (AY095535); MmTDH_cDNA (AY116662); rat, Rattus norvegicus, RmTDH_EST (BF557448); chicken, Gallus gal-
lus, GgTDH_EST (BM491791); western clawed frog, Silurana tropicalis, StTDH_EST (AL638064); zebrafish, Danio rerio,
DrTDH_ESTs; the tunicate, Ciona intestinalis, CiTDH_ESTs; fruit fly, Drosophila melanogaster, DmTDH_gDNA (AAF51607); the
nematode, Caenorhabditis elegans, CeTDH_ESTs and the euglenoid, Trypanosoma brucei, TbTDH_gDNA (AC084047). There
are no introns in this region of the fly, nematode and trypanosome genes (__). Identical nucleotides and residues are shown by
*, strongly similar residues by: and weakly similar residues by (.).
A
                                      Exon 3/            Intron 3             /Exon 4
                ** **  *   * **** *   * ** **** ** *    *       * * *      * ** ** **  ****  *  *  *  **** ***
HsTDH_gDNA_A    AAACCCCCCGATCATGTCTTTCACAGTGgtaagagatcaatag....ttatgttccttgcagGTCCATTCATTTATTCTGATATCTTGGATTAC
HsTDH_gDNA_B    AAACCCCCCGATCATGTCTTTCACAGTGgtaagagatcaatag....ttatgttccttgcggGTCCATTCATTTATTCTGATATCTTGGATTAC
HsTDH_ORF       K  P  P  D  H  V  F  H  S  G                                    P  F  I  Y  S  D  I  L  D  Y  
MmTDH_gDNA AAGCCCCCTGCTCATGTCTTCCACAGTGgtaagatatagatgg....ctctgtgattaacagGCCCGTTTGTTTATGCCAACATCTTGGATTAC
MmTDH_ORF       K  P  P  A  H  V  F  H  S  G                                    P  F  V  Y  A  N  I  L  D  Y  
TrTDH_gDNA      AAGCCTTCGCCTGATGTTTATAAGAGCGgtatgagactttttt....ttctttgtccatcagGCCCGTTTGTTTACGCCGACGTGCTGGACTAC
TrTDH_ORF       K  P  S  P  D  V  Y  K  S  G                                    P  F  V  Y  A  D  V  L  D  Y
                *  *  .     .  *  :  :  *  *                                    *  *  :  *  :  :  :  *  *  *
B
                                   Exon 5/            Intron 5             /Exon 6
              ** **  *    **     * **    ** **     *             ** **    **              *      * ** **  *  *  *  *    ** **
HsTDH_gDNA TCCAAGGTCCACGCGGAGCTCATGGGAGAAgtaagcatcactcag....ttctctttttcatggTATTATCATTACCGGTATGGGTTagATTTCTGATGCCTGAGATATCCTGG
           S  K  V  H  A  E  L  M  G  E                                    Y  Y  H  Y  R  Y  G  L  D  F  *  C  L  R  Y  P  G 
SsTDH_cDNA TCCAAGGTCCACGCAGAGCTCATGGGAGAG                                  TATTATTATTACCGGTATGGGTTAGACTTCCGATGCCTGAGATATCCTGG
           S  K  V  H  A  E  L  M  G  E                                    Y  Y  Y  Y  R  Y  G  L  D  F  R  C  L  R  Y  P  G 
           *  *  *  *  *  *  *  *  *  *                                    *  *  :  *  *  *  *  *  *  *     *  *  *  *  *  *
MmTDH_gDNA TCCAAGGTCCACACAGAGCTCATGGGAGAAgtaagtgtttcttgg....tttcttttttcttagTACTATTATTACCGGTACGTGTTAGATTTTCGGTGCCTGCGTTATCCTGG
RnTDH_EST  TCCAAGGTCCACACGGAGCTCATGGGAGAG                                  TACTATTATTACCGGTATGGGTTAGATTTCCGGTGCCTGAGATATCCTGG
GgTDH_EST  TCCAAGGTTCATGCTGAACTGATGGGAGAG                                  TACTACCATTACCGATATGGCCTCGACTTTCGCTGCCTGAGGTACCCAGG
StTDH_EST  TCCAAAGTCCATGCAGAGCTTATGGGAGAG                                  TATTACCACTACAGATACGGCCTGGACTTCCGGTGTCTCCGTTATCCTGG
DrTDH_ESTs TCTAAAGTCCATGCAGAGCTTATGGGAGAG                                  TACTACCACCACCGTTACGGCCTTGACTTCCGCTGTCTGCGGTACCCTGG
TrTDH_gDNA TCCAAAGTGCACGGAGAGCTGATGGGAGAGgtgagacagtcatcc....cctgtttcttttcagTATCTCCATCATAAATATGGTCTTGACTTCCGTTGCCTACGTTACCCCGG
CiTDH_ESTs GCTAAAGTTCACGCTGAACGTATGGGCGAG                                  TACTACCACCATCGGTTCAACTTGGATTTTCGTTGTCTTCGATTTCCTGG
DmTDH_gDNA TCCAAGGTGCACGCCGAGCTGATTGGCGAA TACTACTACCACAAGTTTGGACTGGACTTCAGATGCCTGCGCTTCCCAGG
CeTDH_ESTs AGTAAAGTATATGCAGAACGTCTCGGAGAA TATTTCAATCATCGGTTTGGGGTTGATTTCAGAAGCATGAGATTCCCGGG
TbTDH_gDNA ACGAAAGTTTACACGGAATTGCTCGGCACG TGGTACCGTCAAAAGTACGGTGTGGATTTCCGCAGTGTGCGTCTACCTGGBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/18
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endothelial cells, glioma cell lines and some leukaemia
cell lines (Fig. 9B). Together, this suggests that the TDH
promoter is still active and is regulated in different cell
types.
Discussion
A search of the human genomic sequences for the TDH
gene identified only one candidate location on chromo-
some 8p23-22. This is the expected site of the human
TDH gene since there are a number of genes that neigh-
bour the TDH genes in the genomes of human, mouse
and puffer fish that are found in common in this locus.
They are the myotubularin related protein 8, the B-lym-
phoid tyrosine kinase and the hypothetical protein
C8orf13. There are differences in the gene order and ori-
entation in the human and puffer fish TDH loci indicating
that there have been re-arrangements in this locus since
the divergence of the human and puffer fish lineages [34].
The human TDH gene contains 3 mutations that disrupt
the gene transcription and translation. There is a loss of
the acceptor splice sites preceding exons 4 and 6 and an
in-frame stop codon in exon 6. A database search of ex-
pressed human sequences identified other TDH cDNAs
and ESTs similar to the 2 cDNA sequences described. The
sequence of the human cerebellum full-length cDNA
clone FLJ25033 (AK057762, NEDO human cDNA se-
quencing project University of Tokyo, Japan) has 2 5'UTR
exons, the first of which corresponds to exon -1 on the
mouse genomic DNA sequence [22]. This clone skips
both exons 4 and 6, and includes the polyadenylation site.
The ORF would encode a truncated 180 residue protein.
Three very similar human ESTs (AI005002, AI243637 and
AI809781) have exon 4 skipped and use the cryptic accep-
tor splice site in exon 6 that was found in clone 2 and pos-
sesses the in-frame stop codon.
The human TDH gene is a pseudogene because in all indi-
viduals examined the gene contains 1 or more mutations
that disrupt RNA splicing which give rise to a variety of
mRNAs in different individuals. In both pig and mouse
TDH cDNAs there was no evidence of alternatively splic-
ing [22]. In humans, arginine-214 is replaced by a stop co-
don. On translation all the human mRNAs would
generate a variety of truncated proteins ranging from 157
to 230 residues, some of which would also contain dele-
tions of residues 96–146; whereas the size of the core of
TDH enzyme (residues 48–364) differs by only 2 residues
in other species, including some bacterial TDH proteins
[22]. The human truncated proteins would be non-func-
Figure 6
Amplicons from individuals with different genotypes for the exon 4 splice acceptor site SNP were digested with the restriction
enzyme AciI (upper panel) and DNA sequenced (lower panel). Undigested samples, UD and digested samples, D. Arrows indi-
cate the polymorphic nucleotide. In an individual homozygous for the splice acceptor site (AG, middle panel) no AciI digest site
is present. In an individual homozygous for loss of the splice acceptor site (GG, right panel) the 158 bp amplicon is cut into
fragments of 104 and 54 bp. In an individual heterozygous for the AG splice acceptor site (RG, left panel) both alleles are
present and the amplicon is only partially digested.
Heterozygous   Splice acceptor  No splice acceptor
UD     D       UD       D       UD       D
158
104
54BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/18
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tional since they would be unable to make appropriate
contacts with the substrates, L-threonine and NAD+. They
have lost most of the carboxy-terminal domain, which by
homology with GALE [26–29], would be expected to bind
L-threonine and also have lost various regions of the
NAD+ binding motif that extends from exon 1 to exon 6.
In comparison, even single point missense mutations in
the human GALE gene disrupt protein function resulting
in epimerase-deficiency galactosemia [35].
At present, no known human genetic disease has been as-
sociated with defects in the threonine dehydrogenase and
2-amino-3-ketobutyrate coenzyme A ligase biochemical
pathway. This may be because the enzymatic activity of L-
serine/threonine dehydratase is sufficient to metabolise L-
threonine in humans. The mitochondrial threonine dehy-
drogenase enzyme is thought to act in the maintenance of
free somatic threonine concentration derived from dietary
threonine [15] suggesting that humans may not be able to
regulate the level of circulating threonine as well as other
mammals. In vertebrates, L-threonine is degraded by two
major enzymatic pathways and attempts to determine
their relative contribution in humans has been by indirect
methods. Zhao et al. measured threonine oxidation by the
production of labelled CO2 in adult humans from la-
belled threonine and concluded that the conversion of
threonine to glycine through the threonine dehydroge-
nase pathway was not important if it exists at all [19].
More recently, Darling et al. used a more sensitive method
to measure the production of labelled glycine and CO2
and suggested that there was some threonine catabolism
via the threonine dehydrogenase pathway, but it account-
ed for only 7–11% of total [21]. Direct demonstration of
the absence of TDH enzymatic activity in human tissues
such as liver remains to be demonstrated. In contrast, in
normally-fed pigs and rats 80 to 87% of L-threonine ca-
tabolism occurs via threonine dehydrogenase [15,16].
Since the TDH gene is not functioning in humans, what
enzyme(s) could be responsible for the small percentage
of threonine catabolism to glycine? In bacteria, threonine
aldolase also yields glycine, but mammals are thought to
lack the "genuine" threonine aldolase [36]. However, ser-
ine hydroxymethyltransferase exhibits a low threonine al-
dolase activity in mammalian liver [36].
Whether the first dehabilitating mutation was the loss of
the splice acceptor site preceding exon 6 or the arginine-
214 to stop codon mutation is unknown, nor is it known
when in human evolution that a functional TDH gene was
lost. However, the arginine codon CGA is used in only
11.1% of arginine residues in humans, being prone to
mutate to a stop codon. The TDH gene has been con-
served throughout evolution, being found in bacteria and
other mammals [22], so why has it not been conserved in
man? How could such a mutation establish its self in the
ancestral population? It is likely that the mutation must
Figure 7
Amplicons from 3 individuals for the exon 6 splice acceptor site were digested with the restriction enzyme Hsp92II. All ampli-
cons were digested showing loss of the splice site. Undigested samples, UD and digested samples, D.
No splice   No splice  No splice
acceptor    acceptor   acceptor
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have conferred some selectable advantage, under the pre-
vailing environmental conditions, on those individuals
who carried it, and arose at a time when the ancestral pop-
ulation was small. Under conditions of protein starvation,
threonine dietary intake could have been a limiting factor
on growth, survival and successful reproduction and a re-
duction in the rate of threonine catabolism would have
conferred a selective advantage on those individuals with
defective TDH gene. Additionally, if we consider that the
threonine catabolism pathway is also a glycine synthesis
pathway, then a reduction in the production of glycine in
inhibitory glycinergic neurons [37] may have contributed
to human neural evolution.
Since humans lack a functioning threonine dehydroge-
nase enzyme and human parasites such as trypanosomes
do possess one (Edgar and Horn, unpublished results,
GenBank AF529241), the parasite threonine dehydroge-
nase enzyme is a potential target for therapeutic interven-
tion. Indeed, in trypanosomes such as Trypanosoma brucei,
which causes sleeping sickness, L-threonine dehydroge-
nase is an important metabolic enzyme and inhibition of
this enzyme by a wide range of sulphydryl reagents, such
as tetraethylthiuram disulphide, leads to a loss of trypano-
some viability [38–40].
Loss of other metabolically important genes in man re-
sults in disease susceptibility. Man and primates are scur-
vy-prone, having lost the L-gulono-gamma-lactone
oxidase gene that is found in most other eukaryotes, and
are unable to synthesize L-ascorbic acid [41]. Man and pri-
mates have also lost the urate oxidase enzyme that cataly-
Figure 8
The human TDH pseudogene is expressed. (A) Clones from 2 individuals were sequenced and mapped to the TDH gene.
Clone 1 skipped exon 6, and the resulting frame-shift generated a premature stop codon in exon 7 (TGA). Clone 2 skipped
exon 4 and utilised a cryptic splice site in exon 6, and the resulting frame-shift generated a premature stop codon in exon 6. (B)
The translation of clone 1 (exon 6 skipped) encoded a truncated 230 residue ORF. The skipped exon 4 in clone 2 does not
alter the reading frame. However, the use of a cryptic splice site in exon 6, results in a premature stop codon in exon 6. Stop
codons are indicated by *.
TGA
TGA
1    2 3    4      5     6      7       8
1    2 3    4      5     6      7       8 2
1
HsTDHcDNA_1  MLFIRMLRRAGQSPACGCWTPVLPVRFLGISPRQIPADANFHSASFSDTDHPRVLITGAL  60
HsTDHcDNA_2  MLFIRMLRRAGQSPACGCWTPVLPVRFLGISPRQIPADANFHSASFSDTDHPRVLITGAL  60
HsTDHgDNA    MLFIRMLRRAGQSPACGCWTPVLPVRFLGISPRQIPADANFHSASFSDTDHPRVLITGAL  60
HsTDHcDNA_1  GQLGVGLANLLRKRFGKDSVILSDIRKPPDHVFHSGPFIYSDILDYKNLREIVVNNRITW 120
HsTDHcDNA_2  GQLGVGLANLLRKRFGKDSVILSDRRKPPDHVFHSG------------------------ 96
HsTDHgDNA    GQLGVGLANLLRKRFGKDSVILSDIRKPPDHVFHSGPFIYSDILDYKNLREIVVNNRITW 120
HsTDHcDNA_1  LFHYSALLSAFGEANVSLARAVNITGLHNILDVAAEHNLQLFVPSTIGAFGPTSPRNPTP 180
HsTDHcDNA_2  --------------------------LHNILDVAAEHNLQLFVPSTIGAFGPTSPRNPTP 130
HsTDHgDNA    LFHYSALLSAFGEANVSLARAVNITGLHNILDVAAEHNLQLFVPSTIGAFGPTSPRNPTP 180
HsTDHcDNA_1  DLCIQRPRTIYGVSKVHAELMGETMQSRFSMMPQSMANSSATWKPARDCP*          230
HsTDHcDNA_2  DLCIQRPRTIYGVSKVHAELMGEISDA*                                 157
HsTDHgDNA    DLCIQRPRTIYGVSKVHAELMGEYYHYRYGLDF*CLRYPGIISADSQPGGGTTDYAVQIF 240
HsTDHgDNA    HDATKHGKFECNLEACTRLPMMYIDDCLRATLEVMEAPAESLSMRTYNVSAMSFTPEELA 300
HsTDHgDNA    QEVLKHVPEFQITYNVDAVRQAIADGWPMNFDDSNARKDWGWKHDFDLPELVTAMLNFHG 360
HsTDHgDNA SESRVAQAN 369
A
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ses the conversion of uric acid to allantoin. This results in
a high concentration of uric acid in the blood, predispos-
ing man to hyperuricemia that can lead to gouty arthritis
and renal stones [42]. Humans have recently lost 2 func-
tional genes involved in sialic acid function. They are the
CMP-N-acetylneuraminic acid hydroxylase gene (CMAH)
[43] and the siglec-like molecule (Siglec-L1) [44]. Howev-
er, no diseases have yet been associated with the loss of
these genes. The CMAH enzyme converts the sialic acid,
N-acetylneuraminic acid to N-glycolylneuraminic acid,
potentially affecting recognition by a variety of endog-
enous and exogenous sialic acid-binding lectins. Siglecs
are immunoglobulin superfamily member lectins that se-
lectively recognize different sialic acids types and siglec-L1
preferentially recognizes N-glycolylneuraminic acid. To
date, no disease has been associated with the loss of the
TDH gene, but humans may not be able to metabolise
high protein diets as efficiently as other mammals.
Conclusions
The human L-threonine 3-dehydrogenase gene is an ex-
pressed pseudogene, which accounts for the very low lev-
Figure 9
Expression of the TDH pseudogene in human tissues and cell types. (A) Expression of the TDH pseudogene in human tissues.
The lanes are: 100 bp marker, m; heart, H; brain, B; placenta, Pl; lung, Lu; liver, L; skeletal muscle, M; kidney, K; pancreas, Pa;
spleen, S; thymus; Th; prostate, Pr; testis, Te; ovary, O; small intestine, I; negative control, (-). (B) Expression of the TDH pseu-
dogene in human cells. RT-PCR for TDH (top panel) and -actin (bottom panel). The cell types examined were: foetal osteob-
last, fO; adult osteoblasts, aO; pulmonary foetal fibroblast, HFL-1, fF; adult fibroblasts, aF; placental microvascular endothelial,
mE; umbilical vein endothelial, uE; alveolar epithelial adenocarcinoma, A549, EA; bronchial epithelial adenocarcinoma, H322,
EH; bronchial smooth muscle, SM; colorectal adenocarcinoma, CaCo2, CE; Epstein-Barr-transformed lymphocyte Ly; erythro-
leukaemia, K562, EK; erythroleukaemia TF1, ET; glioma, U87, G8; glioma, U373, G3; and negative control (-).
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els of threonine oxidation measured in humans by the
production of labelled CO2 from labelled threonine. This
suggests that the L-serine/threonine dehydratase pathway
may be the only route in the catabolism of threonine in
humans. The presence of a functional TDH gene in key
mammal species such as pigs and mice and its loss in man
should be taken into consideration when utilising hepato-
cytes in bioartificial livers and pharmacokinetic studies.
Methods
Genotyping of genomic DNA from individuals by restric-
tion enzyme digests and DNA sequencing
Human genomic DNA was isolated from peripheral
blood [45]. Regions of genomic DNA surrounding exon 4
and 6 splice acceptor sites were amplified by PCR using
primers ATTGCGTGGCTACCAGTGA and CGATCTC-
CCGAAGATTCTTGT for exon 4 and GAATGAGATTTCA-
GAAAAAGGCAGG and AACCAGTTGTTCCTCCTCCA for
exon 6, using the Advantage 2 cDNA polymerase mix (BD-
Clontech, UK). Amplification conditions were: 30 cycles
of 94C for 10 sec and 57C for 10 sec. PCR products were
desalted using the QIAquick PCR purification kit (Qiagen,
UK). Amplicons from the exon 4 splice acceptor site were
digested in appropriate buffer with the restriction enzyme
AciI. Amplicons from the exon 6 splice acceptor site were
digested with the restriction enzyme Hsp92II. The ampli-
cons were also sequenced directly using the big dye termi-
nator cycle sequencing ready reaction kit and AmpliTaq
DNA polymerase FS and run on an ABI 377 automated
DNA sequencers (both from PE Applied Biosystems, UK).
Molecular cloning of human L-threonine dehydrogenase 
cDNAs
Clones encoding the human L-threonine dehydrogenase
cDNA sequence were obtained by touchdown PCR ampli-
fication from liver and lung cDNA libraries using primers
derived from regions of the sequence of the human ge-
nomic DNA clone RP11-110L10 which had homology to
the 5' and 3' ends of the ORF of the porcine TDH cDNA
sequence. The primers were: ATGCTGTTCATTAGGAT-
GCTGA and GTTGGCTTGGGCAACTCTG and the cycling
conditions were 94C for 10 sec, 64C for 10 sec and 72C
for 1 min less -1.0C per cycle for 8 cycles followed by 24
cycles with an annealing temperature of 56C. PCR prod-
ucts were examined by agarose gel electrophoresis and
stained with ethidium bromide. For cloning, PCR prod-
ucts were excised from low-melting point agarose gels and
the agarose digested with agarase (Promega, UK). The
PCR products were cloned into the T-A vector pCR4-
TOPO (Invitrogen, The Netherlands) and sequenced in
both directions.
Tissue and cellular distribution of L-threonine dehydroge-
nase mRNA by RT-PCR
Human cDNA from 14 tissues (BD-Clontech) was ana-
lysed for the relative expression of TDH and the house-
keeping gene, -actin. Approximately, 0.2 ng of oligo-dT
primed cDNA (derived from poly A+ RNA) from each tis-
sue was amplified by PCR using Taq Gold polymerase (AB
Applied Biosystems). For the analysis of TDH expression
in 15 cultured cell isolates and cell lines, total RNA was ex-
tracted using guanidine thiocyanate and treated with
DNase-I to remove any contaminating genomic DNA (to-
tal RNA isolation system, Promega). Total RNA was re-
verse transcribed with random hexamer primers using an
AMV RNase H- reverse transcriptase, ThermoScript (Invit-
rogen). Approximately, cDNA derived from 50 ng of total
RNA was used in each PCR. Tissue and cell master mixes
were divided into gene specific mixes with the addition of
PCR primers to a final concentration of 200 M. The L-
threonine dehydrogenase primers were: exon 7 and 8
boundary, GCCAGGCCATAGCGGAT and exon 8, TGTT-
TCCACCCCCAGTCCTT and produced a 73 bp amplicon
and the -actin primers were as previously described [46]
and produced a 208 bp amplicon. The amplification con-
ditions were; a 10 min hot start to activate the polymerase
followed by 40 cycles of 95C for 15 sec and 60C for 1
min. The amplicons were examined by ethidium bromide
stained agarose gel electrophoresis.
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